VBL Therapeutics to Report Fiscal Year 2018 Financial Results on March 28
March 14 2019 - 8:00AM
VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology
company focused on the discovery, development and commercialization
of first-in-class treatments for cancer, today announced that it
will host a conference call and live audio webcast on Thursday,
March 28th at 8:30am Eastern Time to report fiscal year ended
December 31, 2018 financial results and to provide a corporate
update.
Thursday, March 28th @ 8:30am
Eastern Time |
From the US: |
|
877-407-9208 |
International: |
|
201-493-6784 |
Conference ID: |
|
13687581 |
Webcast: |
|
http://ir.vblrx.com/events-and-presentations/upcoming-events |
About VBLVascular Biogenics Ltd., operating as
VBL Therapeutics, is a clinical stage biopharmaceutical company
focused on the discovery, development and commercialization of
first-in-class treatments for cancer. The Company’s lead oncology
product candidate, ofranergene obadenovec (VB-111), is a
first-in-class, targeted anti-cancer gene-therapy agent that is
positioned to treat a wide range of solid tumors. It is
conveniently administered as an IV infusion once every two months.
It has been observed to be well-tolerated in >300 cancer
patients and demonstrated efficacy signals in an “all comers” Phase
1 trial as well as in three tumor-specific Phase 2 studies.
Ofranergene obadenovec is currently being studied in a potential
registration trial for platinum-resistant ovarian cancer.
INVESTOR CONTACT:Michael RiceLifeSci Advisors,
LLC(646) 597-6979
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Apr 2023 to Apr 2024